Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Autism Speaks Launches Venture Philanthropy Arm

This article was originally published in The Pink Sheet Daily

Executive Summary

Autism Speaks, an advocacy group that has devoted nearly $200 million to basic research on autism spectrum disorders since 2005, is spinning out a venture arm called Delivering Scientific Innovation for Autism to fund efforts by the for-profit sector. The amount of funding involved is “not insignificant,” said Robert Ring, who left Pfizer in 2011 to spearhead the move into the transitional space.

You may also be interested in...

MedImmune Turns To Venture Philanthropy For Cancer ImmunoRx Combination Trials

MedImmune and two non-profit research organizations are collaborating on clinical trials that explore the tricky world of combinations of novel cancer immunotherapies, including three MedImmune compounds in different stages of development.

With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts